Market Cap 2.19B
Revenue (ttm) 17.20M
Net Income (ttm) -102.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.84%
Debt to Equity Ratio 0.20
Volume 136,900
Avg Vol 261,576
Day's Range N/A - N/A
Shares Out 128.00M
Stochastic %K 1%
Beta 2.30
Analysts Strong Sell
Price Target $35.00

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
Mani86
Mani86 Oct. 22 at 12:56 PM
$MESO https://vimeo.com/1128855977?fl=pl&fe=ti Approval of the above indication will take the revenues to billions of dollars.
0 · Reply
Portman62
Portman62 Oct. 21 at 1:34 PM
$MESO very nice, what’s the news?
0 · Reply
Galilee13
Galilee13 Oct. 21 at 5:55 AM
$MESO nice day on the ASX. Over to you NY
0 · Reply
Mani86
Mani86 Oct. 18 at 11:49 PM
$MESO https://ashpublications.org/blood/article-abstract/146/16/1897/546856/Remestemcel-L-rknd-Ryoncil-the-first-approved?redirectedFrom=fulltext
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 16 at 5:00 PM
The attachment compares the FY2028 revenue multiples (market cap & enterprise value) of all commercial-stage oncology focused bios with 1st approvals since 1/1/2020 with market caps of $800MM to $2.5B versus commercial-stage non-oncology with 1st approvals since 1/1/2020. The graphs (raw data at the bottom) visually demonstrate oncology continues to trade at lower multiples than non-oncology by roughly 20%. This means, in theory, all commercial-stage oncology focused bios could run 20% higher & would trade at like multiples in non-oncology. This is not investment advice but Centerview Partners once noted oncology focused M&A multiples were historically 10% higher than non-oncology (the report was from FY2019 per the Tesaro transaction). Of particular note, $SNDX continues to be one of the more compelling opportunities if, and these are huge ifs, SNDX revenue forecasts are credible and if SNDX's drugs are worth peer multiples. $ZYME continues to trade at high multiples. $DAWN $IOVA $MESO
1 · Reply
GFstocktwits
GFstocktwits Oct. 15 at 11:19 AM
$MESO aussie biiotech try RNV or if you luv trumpy dumpy give NOVA asx a go or the other ones that have popped BUT not best to buy high
0 · Reply
GFstocktwits
GFstocktwits Oct. 15 at 11:19 AM
$MESO the time is over....JPMorgan has had their fun from zero to woop ! this co has NO revenue and to me is offensive to have a 4bn mkt cap.....what has it sold ?????revenue ????
2 · Reply
Mani86
Mani86 Oct. 14 at 2:40 AM
$MESO https://stocksdownunder.com/mesoblast-asxmsb-which-direction/
1 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Oct. 12 at 9:20 PM
$VKTX $NKLR $ARAY $IMVT $MESO I reckon the market will be back to where it was on Thursday. What do you think?
1 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Oct. 11 at 8:19 PM
$MESO Very bullish
0 · Reply
Latest News on MESO
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Oct 6, 2025, 7:24 PM EDT - 18 days ago

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch


Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Aug 29, 2025, 12:27 PM EDT - 2 months ago

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript


Successful Commercial Launch of Ryoncil®

Jul 17, 2025, 8:38 PM EDT - 3 months ago

Successful Commercial Launch of Ryoncil®


Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Apr 28, 2025, 7:44 PM EDT - 6 months ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board


First Three Children to Commence Treatment With Ryoncil®

Mar 30, 2025, 7:39 PM EDT - 7 months ago

First Three Children to Commence Treatment With Ryoncil®


Ryoncil® is Now Available for Purchase in the United States

Mar 26, 2025, 8:19 PM EDT - 7 months ago

Ryoncil® is Now Available for Purchase in the United States


Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Feb 28, 2025, 11:38 AM EST - 8 months ago

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript


Mesoblast Financial Results and Corporate Update Webcast

Feb 25, 2025, 6:13 PM EST - 8 months ago

Mesoblast Financial Results and Corporate Update Webcast


Dr. Gregory George MD PhD Joins Mesoblast Board

Feb 23, 2025, 6:33 PM EST - 8 months ago

Dr. Gregory George MD PhD Joins Mesoblast Board


Ryoncil® Commercial Launch Update and Product Pipeline

Jan 30, 2025, 7:11 PM EST - 9 months ago

Ryoncil® Commercial Launch Update and Product Pipeline


Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 18, 2024, 7:30 AM EST - 11 months ago

Mesoblast to be Added to Nasdaq Biotechnology Index


Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Aug 28, 2024, 9:04 PM EDT - 1 year ago

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript


Mesoblast Corporate Presentation at Investor Conference

Jun 2, 2024, 8:23 PM EDT - 1 year ago

Mesoblast Corporate Presentation at Investor Conference


Mani86
Mani86 Oct. 22 at 12:56 PM
$MESO https://vimeo.com/1128855977?fl=pl&fe=ti Approval of the above indication will take the revenues to billions of dollars.
0 · Reply
Portman62
Portman62 Oct. 21 at 1:34 PM
$MESO very nice, what’s the news?
0 · Reply
Galilee13
Galilee13 Oct. 21 at 5:55 AM
$MESO nice day on the ASX. Over to you NY
0 · Reply
Mani86
Mani86 Oct. 18 at 11:49 PM
$MESO https://ashpublications.org/blood/article-abstract/146/16/1897/546856/Remestemcel-L-rknd-Ryoncil-the-first-approved?redirectedFrom=fulltext
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 16 at 5:00 PM
The attachment compares the FY2028 revenue multiples (market cap & enterprise value) of all commercial-stage oncology focused bios with 1st approvals since 1/1/2020 with market caps of $800MM to $2.5B versus commercial-stage non-oncology with 1st approvals since 1/1/2020. The graphs (raw data at the bottom) visually demonstrate oncology continues to trade at lower multiples than non-oncology by roughly 20%. This means, in theory, all commercial-stage oncology focused bios could run 20% higher & would trade at like multiples in non-oncology. This is not investment advice but Centerview Partners once noted oncology focused M&A multiples were historically 10% higher than non-oncology (the report was from FY2019 per the Tesaro transaction). Of particular note, $SNDX continues to be one of the more compelling opportunities if, and these are huge ifs, SNDX revenue forecasts are credible and if SNDX's drugs are worth peer multiples. $ZYME continues to trade at high multiples. $DAWN $IOVA $MESO
1 · Reply
GFstocktwits
GFstocktwits Oct. 15 at 11:19 AM
$MESO aussie biiotech try RNV or if you luv trumpy dumpy give NOVA asx a go or the other ones that have popped BUT not best to buy high
0 · Reply
GFstocktwits
GFstocktwits Oct. 15 at 11:19 AM
$MESO the time is over....JPMorgan has had their fun from zero to woop ! this co has NO revenue and to me is offensive to have a 4bn mkt cap.....what has it sold ?????revenue ????
2 · Reply
Mani86
Mani86 Oct. 14 at 2:40 AM
$MESO https://stocksdownunder.com/mesoblast-asxmsb-which-direction/
1 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Oct. 12 at 9:20 PM
$VKTX $NKLR $ARAY $IMVT $MESO I reckon the market will be back to where it was on Thursday. What do you think?
1 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Oct. 11 at 8:19 PM
$MESO Very bullish
0 · Reply
zipperson
zipperson Oct. 11 at 12:29 AM
$MESO Come right back…so strong!
0 · Reply
zipperson
zipperson Oct. 9 at 5:51 PM
$MESO Good opportunity to add!
0 · Reply
zipperson
zipperson Oct. 8 at 2:43 PM
$MESO Pass $20 will see $30! This is a gem stock. Good luck!
0 · Reply
Mani86
Mani86 Oct. 8 at 1:13 PM
$MESO Short squeeze incoming 🤫
0 · Reply
Hipsterkicks
Hipsterkicks Oct. 7 at 6:04 PM
$MESO I foresee Q4 revenue increasing by 75% or 100% compared to Q3. With the imminent submission of the Revescor BLA, assuming approval and commercialization by end of Q1 2026, the expanded patient market and estimated pricing would support a stock price between $50-100, easy.
1 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Oct. 7 at 5:38 PM
$MESO there we go🚀🚀🚀🚀🚀
0 · Reply
Mani86
Mani86 Oct. 7 at 1:44 PM
$MESO Given the decent revenue numbers big funds will like to take position in mesoblast now. I expect decent price increase from here given more brokerage houses will cover the stock now. Lets get a big partnership on board!!!
1 · Reply
hots
hots Oct. 7 at 9:34 AM
$MESO 21M in sales, that took me by surprise. The market will eventually catch up those are amazing figures. We will need to talk manufacturing expansion in the US soon. GG fingerprints on that release again, well done mate!
0 · Reply
Mani86
Mani86 Oct. 7 at 7:50 AM
$XBI $MESO https://thebull.com.au/news/mesoblast-shares-rise-on-ryoncil-sales-surge/
0 · Reply
AlertsAndNews
AlertsAndNews Oct. 7 at 2:40 AM
$MESO Ryoncil® Revenues Increase 66% in Second Quarter Post Launch Mesoblast announced Ryoncil® (remestemcel-L-rknd) gross revenue of $21.9M for the quarter ended Sept. 30, 2025, up 66% from the prior quarter.
0 · Reply
Mani86
Mani86 Oct. 6 at 11:07 PM
$MESO Record quarter revenue of 21 million dollars , Enjoy the ride :)
1 · Reply
zipperson
zipperson Oct. 6 at 7:32 PM
$MESO Great opportunity to load up!!!
0 · Reply